Charcot-Marie-Tooth Disease Type 1 Caused by Mutation in the EGR2 Gene

Charcot-Marie-Tooth disease type 1 caused by mutation in the EGR2 gene is a rare, inherited nerve disease that mainly affects the nerves of the arms and legs. Doctors call this group of diseases demyelinating hereditary motor and sensory neuropathies, which means the covering of the nerve (the myelin sheath) is damaged and this slows down nerve signals. In this condition, a change (mutation) in the EGR2 gene upsets how Schwann cells make and keep healthy myelin around peripheral nerves. As a result, nerve signals travel more slowly, muscles become weaker and thinner over time, and feeling in the feet and hands is reduced. Symptoms often start in childhood or early adult life, but they can appear any time from infancy to later adulthood, and the severity can range from very mild to severe. NCBI+3Orpha+3Genetic & Rare Diseases Center+3

Other names

This disease is known by several other names in medical books and research papers. These names are useful to know because you may see them in test reports, research articles, or genetic counseling notes. One common name is Charcot-Marie-Tooth disease type 1D (CMT1D), which tells us it is a subtype of CMT type 1. It is also called EGR2-related Charcot-Marie-Tooth disease, or EGR2-related demyelinating neuropathy, because the problem comes from changes in the EGR2 gene. Some people also use the broader name hereditary motor and sensory neuropathy type I due to EGR2. In severe early-onset cases due to certain EGR2 mutations, doctors may use related labels such as Dejerine–Sottas neuropathy or congenital hypomyelinating neuropathy, which represent very severe forms of the same EGR2-related nerve problem. PMC+3Orpha+3NMD Journal+3

How the EGR2 gene works in the nerves

The EGR2 gene (early growth response 2, also called KROX-20) gives the instructions to make a transcription factor protein that is very important in Schwann cells, the cells that wrap around peripheral nerves to form myelin. EGR2 turns on many myelin genes, such as those for myelin protein zero (MPZ), and helps Schwann cells stop dividing and start making thick, stable myelin. It also turns off genes that belong to immature Schwann cells, so the cells can fully mature. When EGR2 is working normally, nerve fibers are wrapped in healthy myelin, nerve signals are fast, and muscles and sensation stay normal. PNAS+4ScienceDirect+4OUP Academic+4

In EGR2-related Charcot-Marie-Tooth disease, mutations change the structure or function of the EGR2 protein. Some mutations reduce its ability to bind DNA, some disturb how it interacts with helper proteins such as NAB1 and NAB2, and some reduce its overall level or stability. Because of this, myelin genes are not turned on or controlled in the right way, myelin becomes thin, patchy, or unstable, and the nerve fibers show demyelination and remyelination with “onion bulb” changes. This chronic myelin damage slows nerve conduction and eventually leads to secondary loss of axons, which explains the progressive weakness, loss of reflexes, and sensory loss seen in CMT1D. PMC+4Cell+4PMC+4

Types and related EGR2 neuropathies

Doctors often group EGR2-related neuropathies into clinical “types” based on age at onset, severity, and nerve study findings, even though all are caused by changes in the same gene: PMC+4NMD Journal+4Orpha+4

1. Classic CMT1D – A dominantly inherited demyelinating neuropathy with childhood or adolescent onset, slowly progressive distal weakness, foot deformities, and very slow nerve conduction velocities.

2. Adult-onset CMT1D – A milder EGR2-related form where symptoms begin in adulthood and may mimic acquired inflammatory neuropathy; patients can have slowly progressive weakness and sensory loss with demyelinating features on nerve conduction studies. Wiley Online Library+1

3. Early-onset severe CMT1D / Dejerine–Sottas-like neuropathy – Presents in infancy or early childhood with delayed walking, very marked demyelination, severe weakness, and thickened nerves; this can overlap clinically with Dejerine–Sottas syndrome. Abcam+2ScienceDirect+2

4. Congenital hypomyelinating neuropathy due to EGR2 – A very severe form with symptoms from birth, including hypotonia (floppiness), poor breathing, and extremely slow nerve conduction, reflecting markedly reduced myelin at birth. PNAS+2PMC+2

5. Autosomal recessive EGR2 neuropathy – In some families, biallelic (two-copy) EGR2 mutations cause a recessive demyelinating neuropathy, often with severe early onset, showing how different types of EGR2 variants can produce a spectrum of disease. PMC+1

Even when the type names differ, the common theme is damage to myelin-forming Schwann cells caused by altered EGR2 function.

Causes

Here “causes” mainly means what leads to this disease and what can make the nerve problem worse. The primary cause is always a mutation in the EGR2 gene, but other genetic and health factors can modify how severe the disease becomes.

1. Pathogenic mutation in the EGR2 gene – The main direct cause is a disease-causing mutation (variant) in one copy of the EGR2 gene. This variant changes the EGR2 protein so it cannot control myelin genes properly, leading to CMT1D. Orpha+2Global Genes+2

2. Autosomal dominant inheritance of EGR2 variants – In many families, one mutated EGR2 copy is enough to cause classic CMT1D, and each child of an affected parent has a 50% chance to inherit the mutation and develop disease. Orpha+2Clinical Actionability+2

3. Autosomal recessive EGR2 mutations – Some EGR2 mutations cause disease only when both copies of the gene are affected (one from each parent), leading to very severe early-onset demyelinating neuropathy; this is a recessive cause. PMC+2PMC+2

4. De novo (new) EGR2 mutations – In some patients, the EGR2 mutation is not present in either parent but arises spontaneously in the egg or sperm or early embryo, so there is no prior family history even though the mutation causes classic CMT1D. ScienceDirect+2PMC+2

5. Missense mutations in DNA-binding domains – Many disease-causing EGR2 variants are missense changes in the zinc finger regions that bind DNA. These subtle changes can strongly reduce or distort DNA binding, leading to abnormal control of myelin genes. Cell+2ScienceDirect+2

6. Mutations that disrupt EGR2-NAB interactions – Some mutations affect sites where EGR2 interacts with NAB proteins (NAB1, NAB2). These helper proteins fine-tune gene activation and repression; when this partnership is disrupted, Schwann cells fail to mature normally and myelin is unstable. PMC+2Reactome+2

7. Truncating or frameshift mutations – Truncating (nonsense or frameshift) mutations can produce shortened EGR2 proteins that lack important functional domains, leading to severe loss of function and sometimes very early, severe neuropathy. PNAS+2PMC+2

8. Mutations that alter transcriptional activation strength – Some EGR2 variants reduce its ability to turn on down-stream myelin genes even if DNA binding is partly preserved. This weaker activation can cause milder, later-onset forms of CMT1D. Cell+2Wiley Online Library+2

9. Genetic background and modifier genes – Variants in other myelin-related genes (for example PMP22, MPZ, or GJB1) or in pathways that respond to nerve stress may not cause CMT by themselves but can modify the severity or age of onset in a person who already carries an EGR2 mutation. Orpha+2MalaCards+2

10. Family history of inherited neuropathy – A strong family history of CMT-like symptoms suggests shared genetic background that can raise the chance of inheriting an EGR2 mutation or other neuropathy genes in the same family. Mayo Clinic+2NCBI+2

11. Consanguinity (parents related by blood) – When parents are related, such as first cousins, there is a higher chance that both carry the same rare EGR2 variant, which can lead to autosomal recessive forms of EGR2-related neuropathy in their children. PMC+2PMC+2

12. Age-related nerve vulnerability – With increasing age, even normal nerves experience some axonal loss. In someone with an EGR2 mutation and chronic demyelination, this natural age-related change can add to nerve damage and make symptoms more obvious. NCBI+2Clinical Actionability+2

13. Coexisting diabetes mellitus – Diabetes can cause its own peripheral neuropathy. In a person with EGR2-related CMT, diabetes does not cause the disease but can worsen nerve damage, speed up loss of feeling, and increase the risk of foot ulcers and infections. Mayo Clinic+2NCBI+2

14. Chronic alcohol misuse – Long-term heavy alcohol use can damage peripheral nerves and cause nutritional deficiencies such as vitamin B1 deficiency. This does not cause EGR2 mutation, but it can make weakness and numbness much worse in someone who already has CMT1D. NCBI+2Wikipedia+2

15. Chemotherapy or neurotoxic drugs – Some cancer drugs and other medications are known to be toxic to peripheral nerves. In a patient with EGR2-related demyelinating neuropathy, these drugs can add extra axonal damage and increase disability. NCBI+2Clinical Actionability+2

16. Severe vitamin deficiencies (e.g., B12) – Vitamin B12 and other nutrients are important for nerve health. Deficiency will not produce EGR2 mutation but can cause additional neuropathy on top of CMT, making walking and balance problems worse. NCBI+2Wikipedia+2

17. Thyroid disease and other metabolic disorders – Conditions like hypothyroidism can cause or worsen neuropathy. In a person carrying an EGR2 mutation, these metabolic problems can further slow nerves and increase fatigue and weakness. NCBI+2Wikipedia+2

18. Lack of protective foot care – Poor footwear, unrecognized injuries, and chronic pressure on insensate feet can cause ulcers, infections, and joint damage. These complications do not cause the genetic mutation, but they cause additional functional disability in EGR2-CMT. Mayo Clinic+2NCBI+2

19. Severe obesity – Excess body weight increases stress on weak muscles and unstable ankles, making walking harder and raising the risk of falls and joint problems in people with neuropathy. NCBI+2Mayo Clinic+2

20. Lack of early diagnosis and rehabilitation – When the disease is not recognized early, children may miss out on braces, physical therapy, and orthopedic care. Over years, this can allow preventable deformities and contractures to develop, making the eventual disability from the underlying EGR2 neuropathy worse. NCBI+2Clinical Actionability+2

Symptoms

1. Slowly progressive weakness in the feet and ankles – One of the earliest and most typical symptoms is growing weakness of the muscles that lift and move the feet and ankles. Children may trip often, drag their toes, or develop “foot drop.” Over time, climbing stairs and walking on uneven ground become harder. Mayo Clinic+3Orpha+3NCBI+3

2. Muscle wasting in the lower legs (“inverted champagne bottle” legs) – Because the nerve supply to the lower-leg muscles is poor, these muscles shrink with time. The calves become thin while the thighs may look relatively normal, giving a shape sometimes described as “stork legs” or “inverted champagne bottle” legs. Genetic & Rare Diseases Center+3Orpha+3Clinical Actionability+3

3. Weakness in the hands and forearms – As the disease continues, the nerves to the hands may also be affected. This leads to weak grip, difficulty with buttons and zippers, trouble opening jars, and sometimes visible wasting of the small hand muscles. Mayo Clinic+3Orpha+3NCBI+3

4. Foot deformities (high arches and hammertoes) – Many people with CMT1D develop high-arched feet (pes cavus) and curled toes (hammertoes) because of imbalanced muscle pull around the foot. These deformities can cause pain, calluses, and make shoe fitting difficult. Mayo Clinic+3Orpha+3Global Genes+3

5. Unsteady gait and frequent ankle sprains – Weak ankle muscles and poor sensation around the ankle make the joint unstable. This leads to frequent ankle sprains, falls, and a clumsy, high-stepping gait as the person lifts their feet higher to avoid tripping on dropped toes. Mayo Clinic+3Muscular Dystrophy Association+3Clinical Actionability+3

6. Loss of deep tendon reflexes – Reflexes tested with a reflex hammer, especially at the ankles and knees, are often reduced or absent. This reflects the damage to peripheral nerves that normally carry reflex signals between muscle and spinal cord. Wikipedia+3Orpha+3Clinical Actionability+3

7. Numbness and reduced sensation in feet and hands – Many patients notice numbness, “pins and needles,” or reduced ability to feel light touch, pain, temperature, and vibration, especially in the toes and soles. This sensory loss can spread up the legs and later affect the hands. Genetic & Rare Diseases Center+3Wikipedia+3Mayo Clinic+3

8. Neuropathic pain or burning sensations – Some people develop burning, aching, or shooting pains in the feet and legs due to damaged sensory nerves. Although not everyone with CMT1D has pain, when present it can impact sleep and quality of life. NCBI+2Wikipedia+2

9. Poor balance and tendency to fall – Because of weak muscles, altered joint sense, and foot deformities, balance can be poor. Standing in the dark, walking on uneven ground, or closing the eyes can make the person feel wobbly, and falls become more common. Mayo Clinic+3NCBI+3Wikipedia+3

10. Fatigue and reduced stamina – Walking and standing require more effort for someone with weak distal muscles and unstable joints. Even short distances may cause tiredness, and some people need rest breaks or mobility aids to manage daily activities. NCBI+2Clinical Actionability+2

11. Scoliosis or spine curvature – In some EGR2-related cases, especially with more severe early-onset disease, weakness and imbalance of trunk muscles can lead to curvature of the spine (scoliosis), which may cause back pain or breathing difficulty if severe. Abcam+3Orpha+3Genetic & Rare Diseases Center+3

12. Cranial nerve involvement (double vision, facial weakness) – A small number of patients with EGR2-related neuropathy develop involvement of cranial nerves, leading to symptoms such as double vision (diplopia) or weakness of facial muscles. This reflects that not only limb nerves but also some cranial nerves can be affected. Orpha+2Abcam+2

13. Bilateral vocal cord paresis or hoarseness – Some EGR2 mutation carriers have weakness of the nerves to the vocal cords, leading to hoarse voice, soft speech, breathing noise, or risk of airway problems. This is a distinctive symptom seen in a subset of CMT1D patients. NMD Journal+3Orpha+3Global Genes+3

14. Delayed motor milestones in infants and children – In early-onset and severe forms, babies may be late to sit, crawl, or walk. They may appear floppy, with poor head control and weak limb movements, reflecting early nerve and myelin damage. Orpha+3Abcam+3ScienceDirect+3

15. Breathing or swallowing problems in very severe cases – In rare, very severe EGR2-related neuropathies, weakness of respiratory or swallowing muscles can cause breathing difficulty, poor feeding, or failure to thrive in infancy, and may require intensive medical support. PMC+2Abcam+2

Diagnostic tests:

Physical examination

1. General neurological examination – The doctor first performs a complete neurological exam. They check muscle strength in the legs and arms, look for wasting of muscles, test reflexes with a hammer, and assess different types of sensation in the limbs. In CMT1D, the exam usually shows distal weakness, muscle wasting, reduced or absent reflexes, and “stocking-glove” sensory loss. MalaCards+3NCBI+3Orpha+3

2. Foot and limb inspection – The clinician carefully looks at the shape of the feet, ankles, legs, and hands. They look for high arches, hammertoes, calluses, ankle deformities, thin calf muscles, and wasting of the small hand muscles. These visual signs strongly suggest a long-standing hereditary neuropathy. Wikipedia+3Orpha+3Global Genes+3

3. Gait observation and walking tests – The doctor watches the patient walk normally, on heels, on toes, and sometimes along a straight line. A high-stepping gait, toe dragging, foot drop, and difficulty walking on heels are typical features of CMT1, including CMT1D. MalaCards+3Muscular Dystrophy Association+3NCBI+3

4. Spine and posture examination – The spine is checked for curvature (scoliosis or kyphosis), shoulder and pelvic alignment, and rib cage shape. In more severe EGR2-related neuropathy, scoliosis and abnormal posture can be clues to long-standing neuromuscular weakness. Orpha+2Abcam+2

Manual and functional tests

5. Manual muscle testing (MRC scale) – The examiner tests individual muscle groups by hand, asking the patient to push or pull against resistance. Each muscle is graded from 0 (no movement) to 5 (normal strength). In CMT1D, distal muscles such as ankle dorsiflexors and intrinsic hand muscles often score lower than proximal muscles. Wikipedia+3NCBI+3Orpha+3

6. Heel-toe walking and tandem gait – Asking the patient to walk on heels, then on toes, and finally in a straight line placing one foot in front of the other tests both strength and balance. Difficulty with heel walking reflects weakness of muscles that lift the foot, while poor tandem gait indicates balance problems due to sensory loss and weakness. NCBI+2Muscular Dystrophy Association+2

7. Romberg and balance tests – In the Romberg test, the patient stands with feet together, first with eyes open and then with eyes closed. Increased swaying or loss of balance with eyes closed suggests impaired joint position sense in the legs, a common feature in demyelinating neuropathies like CMT1D. NCBI+2Wikipedia+2

8. Functional hand tests (fine motor tasks) – Simple tasks such as buttoning, writing, picking up small objects, or opening containers are observed. Difficulty performing these actions supports the presence of distal hand weakness and sensory loss, which are common in more advanced CMT1D. Muscular Dystrophy Association+3NCBI+3Orpha+3

Laboratory and pathological tests

9. Basic blood tests to exclude other neuropathy causes – Blood tests may include glucose (for diabetes), vitamin B12, folate, thyroid function, kidney and liver tests, and sometimes autoimmune markers. Although results are usually normal in pure CMT1D, these tests help rule out acquired causes of neuropathy that can mimic or worsen hereditary neuropathies. Orpha+3NCBI+3Mayo Clinic+3

10. Cerebrospinal fluid (CSF) analysis in severe cases – In patients with early-onset or very severe EGR2-related neuropathy, a lumbar puncture may show raised protein levels in the CSF while cell counts stay normal. This pattern reflects widespread demyelination, similar to that seen in Dejerine–Sottas syndrome. Abcam+2PMC+2

11. Nerve biopsy (sural nerve biopsy) – A small sensory nerve, often the sural nerve at the ankle, can be removed and examined under the microscope. In CMT1D and other demyelinating CMTs, biopsy may show loss of myelin, “onion bulb” formations from repeated demyelination and remyelination, and hypertrophic changes in Schwann cells. This test is used less often today because genetic testing is available, but it remains a classical pathological confirmation. NCBI+3Orpha+3PNAS+3

12. Peripheral neuropathy gene panel (next-generation sequencing) – A blood sample can be sent for a panel that includes dozens or hundreds of neuropathy-related genes. This test screens for mutations in EGR2 and other genes and is often the first genetic test ordered when CMT is suspected, because it is efficient and cost-effective. MalaCards+3PMC+3Orpha+3

13. Targeted EGR2 gene sequencing and variant analysis – If a panel or clinical suspicion points strongly to EGR2, direct sequencing of this gene is performed. The lab looks for missense, nonsense, frameshift, and splice-site variants and interprets them according to international guidelines. Identifying a pathogenic EGR2 variant confirms the diagnosis of CMT1D. ScienceDirect+3NMD Journal+3PMC+3

Electrodiagnostic tests

14. Motor nerve conduction studies (NCS) – Electrodes are placed on the skin over nerves and muscles. The nerve is stimulated electrically, and the response is recorded. In CMT1D, motor conduction velocities are markedly slowed, often below 38 m/s in arms, showing a demyelinating pattern, while amplitudes may be near normal early and reduced later when axonal loss occurs. Muscular Dystrophy Association+3Orpha+3Clinical Actionability+3

15. Sensory nerve conduction studies – Similar tests are done on sensory nerves in the arms and legs. In demyelinating CMT1, sensory conduction velocities are also slow, and sensory nerve action potentials may be reduced or absent, matching the sensory loss reported by patients. MalaCards+3Orpha+3NCBI+3

16. Electromyography (EMG) – A fine needle electrode is inserted into muscles to record electrical activity. EMG in CMT1D can show signs of chronic denervation and reinnervation, such as large, long-duration motor unit potentials, reflecting secondary axonal loss due to long-term demyelination. Muscular Dystrophy Association+3Orpha+3NCBI+3

17. Advanced nerve conduction and excitability studies – In some research or specialized centers, more detailed electrodiagnostic tests, such as F-wave studies or nerve excitability measurements, are used to better characterize demyelination and distinguish hereditary demyelinating neuropathies (like CMT1D) from acquired immune-mediated neuropathies. Orpha+3ResearchGate+3Wiley Online Library+3

Imaging tests

18. MRI of peripheral nerves (MR neurography) – Magnetic resonance imaging of the limbs can show thickened peripheral nerves and abnormal signal in nerve roots or plexuses in demyelinating neuropathies. In EGR2-related CMT1D, MRI may reveal nerve enlargement and sometimes muscle atrophy and fatty replacement, helping to confirm the pattern of chronic neuropathy. Muscular Dystrophy Association+3ResearchGate+3Orpha+3

19. Spine MRI – If scoliosis or other spinal deformities are present, MRI of the spine may be done to assess the spinal cord and nerve roots and to help in planning orthopedic or neurosurgical management, especially in severe childhood-onset EGR2-related disease. Orpha+2Abcam+2

20. X-rays or CT of feet and ankles – Plain X-rays or CT scans of the feet and ankles can show high arches, hammertoes, joint subluxation, and other bony deformities. These images are important for orthopedic and rehabilitation planning, even though they do not show nerve damage directly. Wikipedia+3Mayo Clinic+3NCBI+3

Non-Pharmacological Treatments (Therapies And Others)

There is no cure and no approved disease-modifying drug for Charcot–Marie–Tooth disease type 1 (CMT1) caused by EGR2 mutation. Care focuses on reducing symptoms, keeping muscles and joints flexible, and preventing deformity with rehabilitation, orthoses and sometimes surgery.PMC+1

Physiotherapy (Physical Therapy)
Physiotherapy is a core treatment for CMT1. A physiotherapist teaches stretching, balance and strengthening exercises for feet, ankles, legs and sometimes hands. The purpose is to keep muscles as strong and flexible as possible and to slow contractures and joint stiffness. It works by using repeated, low-impact movement to maintain nerve–muscle connections and protect joints.nhs.uk+1

Occupational Therapy
Occupational therapy focuses on daily tasks like dressing, writing, cooking and using a computer. The purpose is to help people stay independent at home, school and work. The therapist suggests different ways of doing activities and may provide tools like special cutlery or pens. It works by adapting the environment and tasks to match the person’s hand weakness and balance problems.Dove Medical Press

Ankle-Foot Orthoses (AFOs)
AFOs are custom braces that support the ankle and foot. Their purpose is to improve walking, reduce tripping and support weak muscles that cause foot drop. They work by holding the ankle in a stable, slightly flexed position and redistributing pressure under the foot so walking becomes more stable and less tiring.ResearchGate+1

Custom Shoes And Insoles
Supportive shoes and cushioned insoles help correct mild deformity and spread pressure more evenly. The purpose is to improve comfort, balance and walking efficiency. They work by giving a stable base, improving grip on the ground, and preventing painful pressure points and skin breakdown, especially when the person has reduced feeling in the feet.

Strengthening Exercises
Gentle resistance exercises for legs, hips and core are often prescribed. The purpose is to maintain remaining muscle strength without over-fatiguing weak nerves. They work by stimulating muscle fibres that still receive nerve signals, helping them stay strong and support joints. Exercises must be low to moderate intensity and guided by a therapist to avoid overuse.

Stretching And Range-Of-Motion Exercises
Regular stretching of calves, hamstrings and foot muscles helps stop tendons from shortening. The purpose is to prevent contractures and fixed deformities that make walking harder and more painful. Stretching works by slowly lengthening muscles and tendons, keeping joints like the ankle and toes flexible so braces and shoes fit better.nhs.uk

Balance And Proprioception Training
CMT1 damages sensory nerves, so the brain receives weaker signals about foot position. Balance exercises using foam pads, balance boards or simple single-leg stands aim to retrain these systems. The purpose is to reduce falls and improve confidence when walking. They work by challenging the balance system in a safe way so the brain learns to use vision and remaining sensation more effectively.ScienceDirect

Gait Training
A physiotherapist can analyse how a person walks and then teach new patterns, including how to use AFOs and walking aids correctly. The purpose is to make walking smoother, safer and more energy-efficient. It works by practising step length, foot placement and timing, and by strengthening key muscles that support the hips, knees and ankles.

Walking Aids (Canes, Walkers)
Some people with CMT1 benefit from a cane, crutch or walker. The purpose is to improve safety and reduce the risk of falls on uneven ground or stairs. These aids work by giving extra points of support, allowing weight to be shared between arms and legs, and providing a wider base of support for balance.

Hydrotherapy (Aquatic Therapy)
Hydrotherapy uses warm water pools to allow exercise with less strain. The purpose is to improve strength, flexibility and cardiovascular fitness without overloading weak muscles. Water supports body weight and provides gentle resistance, so movements that are difficult on land become easier and safer in the pool.

Pain Psychology And Coping Skills Training
Living with chronic neuropathic pain and disability is stressful. Sessions with a psychologist or counsellor can teach relaxation, pacing and cognitive-behavioural strategies. The purpose is to reduce the emotional burden of pain and improve quality of life. It works by changing how the brain processes pain signals and by helping the person plan activity and rest in a realistic way.

Podiatry (Foot Care)
Regular visits to a podiatrist help prevent complications such as calluses, ulcers and ingrown nails, especially when sensation is reduced. The purpose is to keep the skin and nails healthy and reduce infection risk. It works through careful nail cutting, pressure redistribution with insoles, and early treatment of minor foot problems.ScienceDirect+1

Ergonomic And Home Modifications
Simple changes such as grab bars in the bathroom, non-slip mats, ramps and raised toilet seats can make daily life safer. The purpose is to reduce falls and fatigue. These changes work by matching the environment to the person’s balance and strength limits, so tasks need less effort and carry less risk.

Energy Conservation And Pacing
People with CMT1 often tire easily. Learning to break tasks into smaller steps, plan rests and prioritise important activities is helpful. The purpose is to preserve energy for meaningful tasks and avoid over-fatigue. This works by spreading physical load across the day and week, rather than doing everything at once.

Genetic Counselling
CMT1 due to EGR2 mutation is inherited. Genetic counselling helps families understand inheritance patterns, testing options and reproductive choices. The purpose is to provide clear information and emotional support. It works by explaining risk in simple terms and helping families make informed decisions about future pregnancies.

Psychosocial Support And Support Groups
Meeting others with CMT or speaking with social workers and counsellors can reduce isolation. The purpose is to support mental health and resilience. It works by sharing experiences, practical tips and coping strategies, and by helping people access disability benefits or school/work accommodations.

School And Workplace Accommodations
Some people need extra time, modified duties or assistive technology at school or work. The purpose is to keep people engaged in education and employment. It works by adjusting tasks, providing adapted keyboards or seating, and allowing flexible schedules to manage fatigue and appointments.

Weight Management And General Fitness
Extra body weight increases strain on weak feet and ankles. Gentle aerobic exercise such as swimming or cycling, combined with healthy eating, helps. The purpose is to reduce joint stress and improve cardiovascular fitness. It works by lowering load on bones and joints and improving overall stamina.Dove Medical Press+1

Regular Monitoring By A Neuromuscular Team
Follow-up with a neurologist, rehabilitation specialist, physiotherapist and orthopaedic surgeon allows early detection of problems such as progressive deformity or new weakness. The purpose is timely adjustment of braces, therapies and, when needed, surgery. It works by tracking changes over time instead of waiting for severe disability.

Falls-Prevention Education
Teaching people how to move safely on stairs, in the bathroom and outdoors is important. The purpose is to avoid fractures and serious injuries. It works by combining home changes, balance training, suitable footwear and awareness of fatigue signs so the person can plan safer routes and activities.

---

Drug Treatments

Currently there are no FDA-approved drugs that cure CMT1 or specifically target EGR2-related neuropathy. Drug treatment is aimed at neuropathic pain, muscle cramps, sleep and mood problems. Doses below are general ranges from FDA-labelled uses (such as diabetic neuropathic pain) and must be tailored by a doctor.Physiopedia+1

Duloxetine (SNRI Antidepressant)
Duloxetine is a serotonin–norepinephrine reuptake inhibitor used for neuropathic pain and depression. For nerve pain, adults often take 60 mg once daily. It is used in CMT to reduce burning, shooting pain. It works by boosting serotonin and norepinephrine in the spinal cord, which dampens pain signals. Side effects can include nausea, dry mouth, sleep changes and raised blood pressure.FDA Access Data+1

Pregabalin (Gabapentinoid)
Pregabalin is approved for various neuropathic pains. Usual doses for nerve pain are 150–600 mg per day in divided doses. In CMT it can reduce burning, tingling and shooting pain. It binds to calcium channels on nerve cells and reduces release of excitatory neurotransmitters. Side effects include dizziness, sleepiness, weight gain and ankle swelling.

Gabapentin (Gabapentinoid)
Gabapentin is another nerve-pain medicine, often started at 300 mg at night and slowly increased, sometimes up to 1 800–3 600 mg/day. It reduces abnormal firing in damaged sensory nerves. The purpose is to lessen neuropathic pain and improve sleep. Common side effects are dizziness, tiredness, swelling and weight gain.

Amitriptyline (Tricyclic Antidepressant)
Amitriptyline is used in low doses (10–75 mg at night) for neuropathic pain and sleep. It blocks reuptake of serotonin and norepinephrine and also blocks certain pain-related receptors. In CMT it can improve sleep and reduce pain at night. Side effects include dry mouth, constipation, blurred vision and drowsiness, so it must be used carefully.

Nortriptyline (Tricyclic Antidepressant)
Nortriptyline is similar to amitriptyline but sometimes better tolerated. Doses for nerve pain might range from 10–75 mg at night. It is used to reduce chronic neuropathic pain and improve mood. It works by increasing serotonin and norepinephrine and modulating pain pathways. Side effects include dry mouth, constipation, dizziness and heartbeat changes.

Carbamazepine (Sodium Channel Blocker)
Carbamazepine is an anti-seizure drug sometimes used for sharp, shooting nerve pain. Doses vary but often start around 100–200 mg twice daily and increase slowly. It stabilises over-active sodium channels in nerves. Side effects can include dizziness, nausea, low sodium and rare but serious blood and skin reactions, so blood tests and monitoring are needed.

Topiramate (Anti-Seizure Drug)
Topiramate can be used for neuropathic pain and migraine. Typical doses range from 50–200 mg per day. It works by blocking certain ion channels and enhancing inhibitory GABA activity, which calms over-active nerves. Side effects include tingling in hands and feet, weight loss, confusion and kidney stone risk.

Tramadol (Weak Opioid And SNRI)
Tramadol is a painkiller that has both opioid and serotonin–norepinephrine reuptake inhibition actions. Doses are usually 50–100 mg every 4–6 hours as needed, with a maximum set by the doctor. It can help when other pain drugs are not enough, but it carries risks of dependence, drowsiness, nausea and seizures, so it should be used carefully and short-term.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs: Ibuprofen, Naproxen)
NSAIDs help with musculoskeletal and joint pain, not neuropathic pain directly. Ibuprofen (e.g., 200–400 mg every 6–8 hours) or naproxen (e.g., 250–500 mg twice daily) can reduce aching around joints, especially after activity or surgery. They work by blocking prostaglandin production. Side effects include stomach irritation, kidney strain and increased bleeding risk.

Acetaminophen (Paracetamol)
Acetaminophen is often used as a first-line mild pain reliever. Doses must stay within safe limits (usually not more than 3–4 g per day in adults). It works mainly in the central nervous system to reduce pain and fever. It is safer for the stomach than NSAIDs but can cause liver damage at high doses, especially with alcohol.

Baclofen (Muscle Relaxant)
Baclofen is a GABA-B receptor agonist used to treat muscle stiffness and cramps. Doses start low (5–10 mg three times daily) and increase slowly. In CMT it may help reduce painful muscle spasms. It works by decreasing excitatory signals from the spinal cord to muscles. Side effects include drowsiness, weakness and dizziness.

Tizanidine (Muscle Relaxant)
Tizanidine is an alpha-2 adrenergic agonist used for spasticity and muscle tightness. Doses often start at 2–4 mg and are increased as needed. It reduces muscle tone by acting on spinal interneurons. Side effects include sleepiness, low blood pressure and dry mouth, so monitoring is important.

Clonazepam (Benzodiazepine)
Clonazepam can help with tremor, muscle jerks and night-time cramps in some people. Doses are usually low and given at night. It enhances GABA signalling and calms excessive nerve firing. Because it can cause dependence, drowsiness and memory problems, doctors use it cautiously and for limited periods.

Topical Lidocaine (Local Anesthetic Patches Or Gels)
Lidocaine patches or gels can be applied over painful areas of skin. The purpose is to numb superficial nerve endings and reduce burning or allodynia. They work by blocking sodium channels in peripheral nerves in the skin. Side effects are usually mild, such as local redness or irritation.

Capsaicin Cream Or Patch
Capsaicin is a compound from chili peppers that depletes substance P from pain fibres. Low-strength creams are applied several times per day, while high-dose patches are used under medical supervision. The purpose is to reduce local nerve pain over weeks. It can cause strong burning at first, which then settles as nerves become less sensitive.

Antidepressants For Mood (SSRIs, SNRIs)
Many people with chronic diseases like CMT1 also have anxiety or depression. SSRIs and SNRIs (other than duloxetine) are used in standard antidepressant doses. They improve mood, energy and coping. They work by increasing serotonin (and sometimes norepinephrine). Side effects vary by drug but may include stomach upset, sleep changes and sexual side effects.

Sleep Medicines (Short-Term Use)
Short courses of sleep aids (such as melatonin or physician-chosen hypnotics) may be needed when pain seriously disturbs sleep. The purpose is to restore a healthier sleep pattern while other treatments are adjusted. These medicines act on brain receptors related to sleep and must be used under close supervision to avoid dependence and daytime drowsiness.

Drugs To Avoid Or Use With Great Caution
Some chemotherapy drugs and other agents can worsen neuropathy. For example, liposomal vincristine (Marqibo) is contraindicated in people with demyelinating conditions, including Charcot–Marie–Tooth syndrome, because it can cause severe neuropathy.FDA Access Data+1 Always tell every doctor you have CMT1 before starting new medicines.

Clinical Trial Drugs (Example: Baclofen–Naltrexone–Sorbitol Combination)
Some combination drugs have orphan designation for CMT1A but are not yet approved.FDA Access Data These experimental medicines aim to modify myelination or gene expression. Doses are decided only in trials, and they should not be used outside regulated studies.

Overall Drug Strategy
Drug treatment is usually layered: start with safer options like duloxetine, gabapentin-type drugs or tricyclics for neuropathic pain, add simple painkillers when needed, and consider stronger medicines only if benefits outweigh risks. Regular review is essential to adjust doses and limit side effects.Dove Medical Press+1

---

Dietary Molecular Supplements

Evidence for supplements in CMT1 is limited. These products should not replace prescribed treatment, and doses must be checked with a doctor.

Omega-3 Fatty Acids (Fish Oil)
Omega-3 fatty acids have anti-inflammatory and membrane-stabilising effects. They may support nerve cell membranes and general cardiovascular health. Typical supplement doses are 1–3 g/day of EPA+DHA, taken with food. They reduce inflammatory mediators and may improve blood flow. Side effects can include fishy after-taste and, at high doses, increased bleeding tendency.

Vitamin B12
Vitamin B12 is essential for myelin and nerve function. In people with low or borderline B12, supplements (oral or injections) can protect nerves. Oral doses often range from 500–1 000 µg/day. It works as a co-factor in DNA and myelin synthesis. Side effects are rare but can include mild stomach upset.

Vitamin B1 (Thiamine) And Benfotiamine
Thiamine helps energy production in nerves. Benfotiamine is a fat-soluble form with better absorption, sometimes used at 150–300 mg/day in neuropathy. It reduces harmful sugar-related by-products and oxidative stress in nerves. Side effects are usually mild and include gastrointestinal discomfort.

Vitamin B6 (Pyridoxine – Cautious Dosing)
Vitamin B6 is needed for neurotransmitter synthesis, but high doses can actually cause neuropathy. Low doses (for example, under 50 mg/day unless supervised) may support normal nerve function if someone is deficient. It works in many enzyme systems. Because toxicity can mimic neuropathy, any high-dose use must be monitored.

Folate (Vitamin B9)
Folate is important for DNA synthesis and nerve health. In deficiency, 400–800 µg/day is often used. It supports cell division and repair. In CMT, correcting deficiency may optimise nerve function but will not reverse genetic damage. Side effects are rare at standard doses.

Vitamin D
Vitamin D supports bone health and muscle function. Many people have low levels, especially if mobility is reduced. Doses vary (e.g., 800–2 000 IU/day) depending on blood levels. It works by regulating calcium and bone metabolism and may help muscle strength. Excess doses can cause high calcium and kidney problems.

Alpha-Lipoic Acid
Alpha-lipoic acid is an antioxidant used in diabetic neuropathy studies. Typical doses are around 300–600 mg/day. It may reduce oxidative stress and improve microcirculation around nerves. Some people report improved burning pain, but evidence in CMT is limited. Side effects include nausea and skin rash in some individuals.

Acetyl-L-Carnitine
Acetyl-L-carnitine is involved in mitochondrial energy production. Doses in studies range from 500–1 000 mg two or three times daily. It may support nerve regeneration and reduce pain by improving energy supply in neurons. Side effects can include nausea and restlessness in some users.

Coenzyme Q10
CoQ10 is another mitochondrial co-factor. Doses of 100–300 mg/day are common. It helps in electron transport and antioxidant defence. In theory it may support muscle and nerve energy, although strong data in CMT1 are lacking. Side effects are usually mild, such as stomach upset.

Magnesium
Magnesium aids muscle relaxation and nerve conduction. Supplements of 200–400 mg/day may help with cramps in some people. It works by modulating calcium channels and NMDA receptors. Too much magnesium can cause diarrhoea and, in severe overdose or kidney disease, low blood pressure and heart rhythm problems.

---

Regenerative, Immunity-Related And Stem Cell Approaches

At present, there are no approved regenerative or stem cell drugs specifically for CMT1 due to EGR2 mutation. Research is ongoing, and any such treatment should only be given inside registered clinical trials.PMC+1

Researchers are studying several directions, including gene therapy to correct or silence faulty myelin genes, viral vectors carrying normal copies of genes, antisense or siRNA molecules that lower harmful protein levels, neurotrophic factors that support Schwann cells and experimental stem cell approaches. Some gene therapies for other CMT types, such as AAV9-based treatments and siRNA targeting PMP22, already have orphan designation but are not yet approved for regular clinical use.FDA Access Data+1

Immune-modulating therapies such as IVIG or steroids are not standard for classic inherited CMT1 but may be considered if there is suspicion of an overlapping immune neuropathy. These medicines have important risks and are strictly specialist treatments.

Because these approaches are complex and still experimental, you should always discuss any “regenerative” or “stem cell” offers with a neurologist who has expertise in CMT and check that any study is officially registered and ethically approved.

---

Surgeries

Foot And Ankle Deformity Correction
Many people with CMT1 develop high arches (pes cavus), claw toes and ankle instability. Orthopaedic surgery can realign bones, lengthen tight tendons and balance muscles. The purpose is to improve standing, walking and shoe fit and to reduce pain. Surgery works by correcting the mechanical position of the foot to match the pattern of muscle weakness.Charcot-Marie-Tooth Association+1

Tendon Transfers
In tendon transfer surgery, a stronger tendon is moved to replace a weak or non-functioning one, for example to lift the foot. The purpose is to restore active dorsiflexion and improve clearance during walking. It works by rerouting the pull of muscles so that remaining strength is used more effectively.

Osteotomies (Bone Cuts And Realignment)
Osteotomies involve cutting and re-shaping bones of the foot (such as the calcaneus or metatarsals) to correct cavus or varus deformity. The purpose is to achieve a more plantigrade, stable foot. They work by changing bone angles so weight is spread more evenly across the sole, reducing pain, calluses and ankle sprains.

Joint Fusion (Arthrodesis)
In severe deformity or arthritis, fusing joints in a corrected position can provide stability and pain relief. The purpose is to create a solid, painless platform for standing and walking when movement in that joint is already poor and painful. It works by removing joint surfaces and allowing bones to heal as one piece.

Hand And Upper Limb Surgery (Selected Cases)
Some people develop severe hand deformity or weakness that affects function. Surgery such as tendon transfers or joint stabilisation in the hand may be offered in specialised centres. The purpose is to improve grip, pinch and fine tasks. It works by improving alignment and giving stronger muscles a mechanical advantage.

---

Preventions And Risk-Reduction Strategies

Because CMT1 due to EGR2 mutation is genetic, we cannot completely prevent the disease, but we can prevent or delay many complications:

1. Start physiotherapy and stretching early to slow contractures and joint stiffness.

2. Use braces, insoles and proper footwear as soon as gait changes appear to reduce falls and deformity.nhs.uk+1

3. Avoid nerve-toxic medicines (like certain chemotherapy drugs) whenever safer alternatives exist; always remind doctors you have CMT.FDA Access Data+1

4. Keep weight in a healthy range to reduce stress on weak feet and ankles.

5. Protect feet from injury, for example by wearing shoes indoors if sensation is reduced.

6. Do regular skin and nail checks to spot sores, blisters or infections early.

7. Stay physically active at a safe level, using low-impact activities like swimming or cycling.

8. Manage mood and stress, since depression and anxiety can worsen pain and fatigue.

9. Attend regular neurology and orthopaedic reviews so problems are caught before they become severe.

10. Seek genetic counselling to understand family risk and reproductive options.

---

When To See Doctors

You should see a doctor, ideally a neurologist with experience in hereditary neuropathies, if you or your child notice progressive foot deformities, frequent tripping, weakness in legs or hands, or a strong family history of similar problems. You should return promptly if pain suddenly worsens, new numbness or weakness appears, or walking becomes much harder. Sudden severe pain, rapid change in sensation, or bladder or bowel problems may point to another emergency condition and need urgent evaluation. Before any major new medicine or surgery, you should also consult your neuromuscular team to check for added nerve risk.

---

What To Eat And What To Avoid

What To Eat

1. Balanced meals with whole grains, lean protein, fruits and vegetables to support general health, weight control and muscle maintenance.

2. Adequate protein from fish, poultry, eggs, beans and lentils to help repair muscles and tissues affected by weakness.

3. Foods rich in B vitamins (whole grains, leafy greens, legumes) to support normal nerve metabolism.

4. Calcium and vitamin D sources (dairy, fortified plant milks, small fish with bones) to protect bones when mobility is reduced.

5. Healthy fats including omega-3s from oily fish, flaxseed and walnuts to support cardiovascular health and possibly modulate inflammation.

What To Avoid Or Limit

1. Excess sugary drinks and sweets, which add weight and may worsen fatigue.

2. Very high salt intake, which can raise blood pressure and strain the heart.

3. Heavy alcohol use, which directly damages peripheral nerves and can worsen neuropathy.

4. Crash diets or extreme fasting, which can lead to muscle loss and weakness.

5. Unregulated “miracle cures” or high-dose supplements, especially vitamin B6, without medical supervision, because some can harm nerves.

---

Frequently Asked Questions (FAQs)

1. Can Charcot–Marie–Tooth disease type 1 caused by EGR2 mutation be cured?
At present there is no cure and no drug that can reverse the underlying genetic problem. Treatment focuses on rehabilitation, orthoses, surgery when needed, pain control and lifestyle changes to reduce complications and maintain function.PMC+1

2. Does everyone with EGR2-related CMT1 become severely disabled?
No. Severity varies widely, even within the same family. Some people have mild lifelong weakness and need only simple braces, while others may need surgery or walking aids. Early therapy, good foot care and avoiding nerve-toxic drugs can help many people stay mobile longer.

3. Are there special medicines for EGR2 mutations?
There are currently no drugs that specifically target EGR2 mutations. Most research focuses on other CMT subtypes, and on broader strategies like gene therapy and myelin-supporting treatments. However, symptom-based medicines for neuropathic pain and muscle cramps can still be very helpful.PMC+1

4. Is exercise safe if I have CMT1?
Yes, but it should be guided by a physiotherapist. Low-impact exercises that avoid over-fatigue, such as swimming, cycling and controlled strengthening, are usually recommended. The goal is to maintain strength and flexibility without overworking weak muscles or risking injury.nhs.uk+1

5. Will surgery fix my CMT?
Surgery can correct foot deformities and improve walking, but it does not change the underlying nerve disease. Nerves may still slowly worsen over time. Surgery is usually considered when braces and therapy are not enough and when deformity causes pain, falls or trouble with shoes.Charcot-Marie-Tooth Association+1

6. Can children with CMT1 play sports?
Many children can take part in adapted sports and physical education. Activities with lower impact and better ankle support are safer. A physiotherapist and doctor can advise which sports are suitable and whether braces or ankle supports are needed.

7. Is pregnancy safe for someone with CMT1?
Most people with CMT can have safe pregnancies, but extra planning is important. Fatigue and weakness may increase, and childbirth positions may need adjustment. Genetic counselling can explain the chance of passing the condition to a child.

8. Should I have genetic testing?
Genetic testing can confirm the diagnosis, identify the specific EGR2 mutation and help with family planning. It can also avoid unnecessary tests for other causes. A genetic counsellor and neurologist can guide you through benefits, limits and emotional impacts.

9. Are there clinical trials for CMT1?
Yes, there are trials for various CMT types. Some involve gene-targeted therapies, while others test new pain treatments or rehabilitation methods. Your neurologist or CMT patient organisations can help you find current trials and decide whether joining is right for you.PMC+2FDA Access Data+2

10. Does diet really affect my nerves?
Diet cannot repair the genetic mutation, but good nutrition supports muscle strength, bone health and energy levels. Avoiding alcohol and extreme diets and correcting vitamin deficiencies may help overall nerve health and reduce complications like falls and fractures.

11. How often should I see my neurologist?
This depends on disease severity. Many people benefit from a review every 6–12 months, with extra visits if new problems appear. Children in growth spurts and people with fast-changing deformity may need more frequent checks.

12. Do braces mean my CMT is getting worse?
Not necessarily. Braces are tools to help you stay active and safe. Using an AFO early can prevent falls and may reduce strain on other joints. Accepting braces or walking aids is often a positive step toward independence, not a sign of failure.

13. Can CMT1 affect other organs?
CMT mainly affects peripheral nerves in the limbs. Some people may have associated issues like scoliosis or mild hand tremor, but serious internal organ involvement is uncommon in typical CMT1. Any new symptoms like breathlessness or chest pain should always be checked separately.

14. Is CMT1 the same as multiple sclerosis?
No. Multiple sclerosis is an immune-mediated disease of the central nervous system (brain and spinal cord). CMT1 is a genetic disease of peripheral nerves and Schwann cells. Treatment and prognosis are different, and CMT1 does not “turn into” MS.

15. What is the long-term outlook?
CMT1 is usually slowly progressive. Many people remain able to walk, often with braces or after foot surgery, for most of their lives. Early rehabilitation, careful foot care, safe exercise, and regular specialist follow-up can greatly improve long-term function and quality of life.Dove Medical Press+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 25, 2025.